Per Soelberg Sørensen

Publikation

Publikationer pr. år 1990 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2023

• 205 Tidsskriftartikel
• 24 Bidrag til bog/antologi
• 19 Review
• 5 Konferenceabstrakt til konference
• 9 Mere
  • 2 Rapport
  • 1 Bog
  • 1 Konferencebidrag i proceedings
  • 1 Kommentar/debat
  • 1 Konferenceabstrakt i tidsskrift
  • 1 Leder
  • 1 Letter
  • 1 Andet bidrag

Publikationer pr. år

Publikationer pr. år

Søgeresultater

• 2023

  Autonomic response to walk tests is useful for assessing outcome measures in people with multiple sclerosis

  Kontaxis, S., Laporta, E., Garcia, E., Guerrero, A. I., Zabalza, A., Matteo, M., Lucia, R., Simblett, S., Weyer, J., Hotopf, M., Narayan, V. A., Rashid, Z., Folarin, A. A., Dobson, R. J. B., Buron, M. D., Leocani, L., Cummins, N., Vairavan, S., Costa, G. D., Magyari, M., & 5 flereSørensen, P. S., Nos, C., Bailón, R., Comi, G. & The Radar-Cns Consortium, 2023, I: Frontiers in Physiology. 14, s. 1145818 1145818.

  Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

  • Walk Test 100%
  • Multiple Sclerosis 73%
  • Autonomic Nervous System 60%
  • Health Care Outcome Assessment 54%
  • Electrocardiography 45%

• Expert opinion on COVID-19 vaccines and cladribine tablets in MS: A plain language summary

  Rieckmann, P., Centonze, D., Giovannoni, G., Hua, L. H., Oreja-Guevara, C., Selchen, D., Sørensen, P. S., Vermersch, P., Wiendl, H., Salloukh, H. & Yamout, B., feb. 2023, I: Neurodegenerative disease management. 13, 1, s. 5-13 9 s.

  Publikation: Bidrag til tidsskrift › Review › peer review

  • Cladribine 100%
  • Expert Testimony 71%
  • Tablets 62%
  • Language 54%
  • Vaccines 51%

• Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data network

  Signori, A., Lorscheider, J., Vukusic, S., Trojano, M., Iaffaldano, P., Hillert, J., Hyde, R., Pellegrini, F., Magyari, M., Koch-Henriksen, N., Sørensen, P. S., Spelman, T., van der Walt, A., Horakova, D., Havrdova, E., Girard, M., Eichau, S., Grand'Maison, F., Gerlach, O., Terzi, M., & 19 flereOzakbas, S., Skibina, O., Van Pesch, V., Sa, M. J., Prevost, J., Alroughani, R., McCombe, P. A., Gouider, R., Mrabet, S., Castillo-Trivino, T., Zhu, C., de Gans, K., Sánchez-Menoyo, J. L., Yamout, B., Khoury, S., Sormani, M. P., Kalincik, T., Butzkueven, H. & Big MS Data Network, jan. 2023, I: Journal of neurology, neurosurgery, and psychiatry. 94, 1, s. 23-30 8 s.

  Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

  • Chronic Progressive Multiple Sclerosis 100%
  • Big Data 98%
  • Latent Class Analysis 81%
  • Registries 16%
  • Growth 10%

• Natalizumab treatment of multiple sclerosis - a Danish nationwide study with 13 years of follow-up

  Buron, M. D., Christensen, J. R., Pontieri, L., Joensen, H., Kant, M., Rasmussen, P. V., Sellebjerg, F., Sørensen, P. S., Bech, D. & Magyari, M., 9 apr. 2023, (E-pub ahead of print) I: Multiple Sclerosis and Related Disorders. 74, s. 104713 104713.

  Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

• Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis: A Danish nationwide study

  Sorensen, P. S., Pontieri, L., Joensen, H., Heick, A., Rasmussen, P. V., Schäfer, J., Ratzer, R., Pihl, C. E., Sellebjerg, F. & Magyari, M., 2023, I: Multiple Sclerosis and Related Disorders. 70, s. 1-9 9 s., 104491.

  Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

  • Cladribine 100%
  • Relapsing-Remitting Multiple Sclerosis 85%
  • Tablets 14%
  • Therapeutics 11%
  • Registries 9%

• The gut microbiota in multiple sclerosis varies with disease activity

  Thirion, F., Sellebjerg, F., Fan, Y., Lyu, L., Hansen, T. H., Pons, N., Levenez, F., Quinquis, B., Stankevic, E., Søndergaard, H. B., Dantoft, T. M., Poulsen, C. S., Forslund, S. K., Vestergaard, H., Hansen, T., Brix, S., Oturai, A., Sørensen, P. S., Ehrlich, S. D. & Pedersen, O., 5 jan. 2023, I: Genome Medicine. 15, 1, s. 1 1.

  Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

  • Gastrointestinal Microbiome 100%
  • Multiple Sclerosis 89%
  • Caudovirales 21%
  • Faecalibacterium prausnitzii 18%
  • Blood Cells 18%
• 2022

  Antidrug Antibodies Against Biological Treatments for Multiple Sclerosis

  Sorensen, P. S., jun. 2022, I: CNS Drugs. 36, 6, s. 569-589 21 s.

  Publikation: Bidrag til tidsskrift › Review › peer review

  • Neutralizing Antibodies 100%
  • Multiple Sclerosis 95%
  • Antibodies 59%
  • Interferons 38%
  • Lymphocyte Depletion 24%
  1 Citationer (Scopus)

• Biopsychosocial Response to the COVID-19 Lockdown in People with Major Depressive Disorder and Multiple Sclerosis

  Siddi, S., Giné-Vázquez, I., Bailon, R., Matcham, F., Lamers, F., Kontaxis, S., Laporta, E., Garcia, E., Arranz, B., Dalla Costa, G., Guerrero, A. I., Zabalza, A., Buron, M. D., Comi, G., Leocani, L., Annas, P., Hotopf, M., Penninx, B. W. J. H., Magyari, M., Sørensen, P. S., & 27 flereMontalban, X., Lavelle, G., Ivan, A., Oetzmann, C., White, K. M., Difrancesco, S., Locatelli, P., Mohr, D. C., Aguiló, J., Narayan, V., Folarin, A., Dobson, R. J. B., Dineley, J., Leightley, D., Cummins, N., Vairavan, S., Ranjan, Y., Rashid, Z., Rintala, A., Girolamo, G. D., Preti, A., Simblett, S., Wykes, T., Pab Members, Myin-Germeys, I., Haro, J. M. & On Behalf Of The Radar-Cns Consortium, 1 dec. 2022, I: Journal of Clinical Medicine. 11, 23, 7163.

  Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

  • Major Depressive Disorder 100%
  • Multiple Sclerosis 84%
  • Heart Rate 58%
  • Depression 42%
  • Social Networking 18%

• Correction to: Antidrug Antibodies Against Biological Treatments for Multiple Sclerosis (CNS Drugs, (2022), 36, 6, (569-589), 10.1007/s40263-022-00920-6)

  Sorensen, P. S., aug. 2022, 1 s.

  Publikation: Andet › Andet bidrag › Forskning

  • ofatumumab 100%
  • Multiple Sclerosis 52%
  • B-Lymphocytes 46%
  • Monoclonal Antibodies 43%
  • Antibodies 33%

• Dimethyl fumarate treatment of primary progressive multiple sclerosis: results of an open-label extension study

  Højsgaard Chow, H., Talbot, J., Lundell, H., Marstrand, L., Gøbel Madsen, C., Bach Søndergaard, H., Bredahl Hansen, M., Solberg Sørensen, P., Siebner, H. R. & Sellebjerg, F., 9 dec. 2022, (E-pub ahead of print) I: Multiple Sclerosis and Related Disorders. 70, s. epub 104458.

  Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

  • Dimethyl Fumarate 100%
  • Chronic Progressive Multiple Sclerosis 88%
  • Intermediate Filaments 20%
  • Light 12%
  • Placebos 12%

• Fitbeat: COVID-19 estimation based on wristband heart rate using a contrastive convolutional auto-encoder

  Liu, S., Han, J., Puyal, E. L., Kontaxis, S., Sun, S., Locatelli, P., Dineley, J., Pokorny, F. B., Costa, G. D., Leocani, L., Guerrero, A. I., Nos, C., Zabalza, A., Sørensen, P. S., Buron, M., Magyari, M., Ranjan, Y., Rashid, Z., Conde, P., Stewart, C., & 10 flereFolarin, A. A., Dobson, R. J., Bailón, R., Vairavan, S., Cummins, N., Narayan, V. A., Hotopf, M., Comi, G., Schuller, B. & Consortium, R-C., mar. 2022, I: Pattern recognition. 123, s. 1-10 10 s., 108403.

  Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

  • mHealth 100%
  • Viruses 90%
  • Long short-term memory 89%
  • Convolutional neural networks 70%

• Forebyggende behandling af multipel sklerose

  Filikci, Z., Schreiber, K. I. & Sørensen, P. S., 2022, I: Månedsskrift for Almen Praksis. s. 34-44 11 s., 13267.

  Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

• Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis

  Lefort, M., Sharmin, S., Andersen, J. B., Vukusic, S., Casey, R., Debouverie, M., Edan, G., Ciron, J., Ruet, A., De Sèze, J., Maillart, E., Zephir, H., Labauge, P., Defer, G., Lebrun-Frenay, C., Moreau, T., Berger, E., Clavelou, P., Pelletier, J., Stankoff, B., & 68 flereGout, O., Thouvenot, E., Heinzlef, O., Al-Khedr, A., Bourre, B., Casez, O., Cabre, P., Montcuquet, A., Wahab, A., Camdessanché, J. P., Maurousset, A., Ben Nasr, H., Hankiewicz, K., Pottier, C., Maubeuge, N., Dimitri-Boulos, D., Nifle, C., Laplaud, D. A., Horakova, D., Havrdova, E. K., Alroughani, R., Izquierdo, G., Eichau, S., Ozakbas, S., Patti, F., Onofrj, M., Lugaresi, A., Terzi, M., Grammond, P., Grand'Maison, F., Yamout, B., Prat, A., Girard, M., Duquette, P., Boz, C., Trojano, M., McCombe, P., Slee, M., Lechner-Scott, J., Turkoglu, R., Sola, P., Ferraro, D., Granella, F., Shaygannejad, V., Prevost, J., Maimone, D., Skibina, O., Buzzard, K., Van der Walt, A., Karabudak, R., Van Wijmeersch, B., Csepany, T., Spitaleri, D., Vucic, S., Koch-Henriksen, N., Sellebjerg, F., Soerensen, P. S., Hilt Christensen, C. C., Rasmussen, P. V., Jensen, M. B., Frederiksen, J. L., Bramow, S., Mathiesen, H. K., Schreiber, K. I., Butzkueven, H., Magyari, M., Kalincik, T. & Leray, E., 30 maj 2022, I: BMC Medical Research Methodology. 22, 1, s. 1-14 14 s., 155.

  Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

  • Natalizumab 100%
  • Fingolimod Hydrochloride 96%
  • Propensity Score 74%
  • Multiple Sclerosis 61%
  • Relapsing-Remitting Multiple Sclerosis 28%
  1 Citationer (Scopus)

• Population Pharmacokinetic-B Cell Modeling for Ofatumumab in Patients with Relapsing Multiple Sclerosis

  Yu, H., Graham, G., David, O. J., Kahn, J. M., Savelieva, M., Pigeolet, E., Das Gupta, A., Pingili, R., Willi, R., Ramanathan, K., Kieseier, B. C., Häring, D. A., Bagger, M. & Soelberg Sørensen, P., mar. 2022, I: CNS Drugs. 36, 3, s. 283-300 18 s.

  Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

  • ofatumumab 100%
  • Multiple Sclerosis 52%
  • B-Lymphocytes 46%
  • Pharmacokinetics 45%
  • Population 23%

• Symptomatisk behandling af multipel sklerose

  Filikci, Z., Schreiber, K. I. & Sørensen, P. S., 2022, I: Månedsskrift for Almen Praksis. s. 706-715 10 s.

  Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

• The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021

  Tur, C., Dubessy, A-L., Otero-Romero, S., Amato, M. P., Derfuss, T., Di Pauli, F., Iacobaeus, E., Mycko, M., Abboud, H., Achiron, A., Bellinvia, A., Boyko, A., Casanova, J-L., Clifford, D., Dobson, R., Farez, M. F., Filippi, M., Fitzgerald, K. C., Fonderico, M., Gouider, R., & 29 flereHacohen, Y., Hellwig, K., Hemmer, B., Kappos, L., Ladeira, F., Lebrun-Frénay, C., Louapre, C., Magyari, M., Mehling, M., Oreja-Guevara, C., Pandit, L., Papeix, C., Piehl, F., Portaccio, E., Ruiz-Camps, I., Selmaj, K., Simpson-Yap, S., Siva, A., Sorensen, P. S., Sormani, M. P., Trojano, M., Vaknin-Dembinsky, A., Vukusic, S., Weinshenker, B., Wiendl, H., Winkelmann, A., Zuluaga Rodas, M. I., Tintoré, M. & Stankoff, B., aug. 2022, I: Multiple Sclerosis Journal. 28, 9, s. 1424-1456 33 s.

  Publikation: Bidrag til tidsskrift › Review › peer review

  • Neuromyelitis Optica 100%
  • Multiple Sclerosis 65%
  • Education 46%
  • Infections 35%
  • SARS Virus 13%
  3 Citationer (Scopus)

• The utility of wearable devices in assessing ambulatory impairments of people with multiple sclerosis in free-living conditions

  Sun, S., Folarin, A. A., Zhang, Y., Cummins, N., Liu, S., Stewart, C., Ranjan, Y., Rashid, Z., Conde, P., Laiou, P., Sankesara, H., Dalla Costa, G., Leocani, L., Sørensen, P. S., Magyari, M., Guerrero, A. I., Zabalza, A., Vairavan, S., Bailon, R., Simblett, S., & 8 flereMyin-Germeys, I., Rintala, A., Wykes, T., Narayan, V. A., Hotopf, M., Comi, G., Dobson, R. J. & RADAR-CNS consortium, 2022, I: Computer Methods and Programs in Biomedicine. 227, 14 s., 107204.

  Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

  • Wearable Electronic Devices 100%
  • Social Conditions 80%
  • Wearable technology 77%
  • Multiple Sclerosis 61%
  • Random forests 36%
• 2021

  Age and sex as determinants of treatment decisions in patients with relapsing-remitting MS

  Sorensen, P. S., Kopp, T. I., Joensen, H., Olsson, A., Sellebjerg, F. & Magyari, M., maj 2021, I: Multiple Sclerosis and Related Disorders. 50, s. 102813 102813.

  Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

  • Relapsing-Remitting Multiple Sclerosis 100%
  • Therapeutics 92%
  • Odds Ratio 51%
  • Recurrence 46%
  • Multiple Sclerosis 23%

• Averting multiple sclerosis long-term societal and healthcare costs: The Value of Treatment (VoT) project

  Tinelli, M., Pugliatti, M., Antonovici, A., Hausmann, B., Hellwig, K., Quoidbach, V. & Sørensen, P. S., sep. 2021, I: Multiple Sclerosis and Related Disorders. 54, s. 103107 103107.

  Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

  • Health Care Costs 100%
  • Multiple Sclerosis 98%
  • Costs and Cost Analysis 57%
  • Smoking Cessation 37%
  • Health Personnel 32%

• Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial

  PRONOUNCE Study Investigators, 19 okt. 2021, I: Circulation. 144, 16, s. 1295-1307 13 s.

  Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

  • acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 100%
  • Leuprolide 78%
  • Gonadotropin-Releasing Hormone 55%
  • Prostatic Neoplasms 44%
  • Hormone Antagonists 43%

• Dimethyl Fumarate Treatment in Patients With Primary Progressive Multiple Sclerosis: A Randomized, Controlled Trial

  Højsgaard Chow, H., Talbot, J., Lundell, H., Gøbel Madsen, C., Marstrand, L., Lange, T., Mahler, M. R., Buhelt, S., Holm Hansen, R., Blinkenberg, M., Romme Christensen, J., Soelberg Sørensen, P., Rode von Essen, M., Siebner, H. R. & Sellebjerg, F., 24 aug. 2021, I: Neurology: Neuroimmunology and NeuroInflammation. 8, 5, s. 1-11 11 s., 0000000000001037.

  Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

  • Dimethyl Fumarate 100%
  • Chronic Progressive Multiple Sclerosis 88%
  • Randomized Controlled Trials 43%
  • Intermediate Filaments 39%
  • Placebos 34%
  7 Citationer (Scopus)

• Early treatment delays long-term disability accrual in RRMS: Results from the BMSD network

  Iaffaldano, P., Lucisano, G., Butzkueven, H., Hillert, J., Hyde, R., Koch-Henriksen, N., Magyari, M., Pellegrini, F., Spelman, T., Sørensen, P. S., Vukusic, S. & Trojano, M., sep. 2021, I: Multiple Sclerosis Journal. 27, 10, s. 1543-1555 13 s.

  Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

  • Time-to-Treatment 100%
  • Multiple Sclerosis 79%
  • Big Data 24%
  • Propensity Score 19%
  • Proportional Hazards Models 16%

• Editorial: Challenges in the diagnosis and treatment of multiple sclerosis

  Sørensen, P. S., 1 jun. 2021, I: Current Opinion in Neurology. 34, 3, s. 275-276 2 s.

  Publikation: Bidrag til tidsskrift › Leder › peer review

• Effect of lateral therapy switches to oral moderate-efficacy drugs in multiple sclerosis: a nationwide cohort study

  Buron, M. D., Kalincik, T., Sellebjerg, F., Sørensen, P. S. & Magyari, M., maj 2021, I: Journal of neurology, neurosurgery, and psychiatry. 92, 5, s. 556-562 7 s.

  Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

  • teriflunomide 100%
  • Multiple Sclerosis 62%
  • Relapsing-Remitting Multiple Sclerosis 58%
  • Dimethyl Fumarate 55%
  • Cohort Studies 48%

• Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice

  Rieckmann, P., Centonze, D., Giovannoni, G., Hua, L. H., Oreja-Guevara, C., Selchen, D., Sørensen, P. S., Vermersch, P., Wiendl, H., Salloukh, H. & Yamout, B., 2021, I: Therapeutic Advances in Neurological Disorders. 14, s. 17562864211058298

  Publikation: Bidrag til tidsskrift › Review › peer review

  • Cladribine 100%
  • Expert Testimony 71%
  • Tablets 62%
  • Vaccination 54%
  • Multiple Sclerosis 50%

• Exposure to passive smoking during adolescence is associated with an increased risk of developing multiple sclerosis

  Oturai, D. B., Bach Søndergaard, H., Koch-Henriksen, N., Andersen, C., Laursen, J. H., Gustavsen, S., Kristensen, J. T., Magyari, M., Sørensen, P. S., Sellebjerg, F., Thørner, L. W., Ullum, H. & Oturai, A. B., feb. 2021, I: Multiple Sclerosis Journal. 27, 2, s. 188-197 10 s.

  Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

  • Tobacco Smoke Pollution 100%
  • Multiple Sclerosis 71%
  • Smokers 45%
  • Odds Ratio 17%
  • Propensity Score 14%

• Highly effective disease-modifying treatment as initial MS therapy

  Schmierer, K., Sørensen, P. S. & Baker, D., 1 jun. 2021, I: Current Opinion in Neurology. 34, 3, s. 286-294 9 s.

  Publikation: Bidrag til tidsskrift › Review › peer review

  • Multiple Sclerosis 100%
  • Immunotherapy 99%
  • ozanimod 57%
  • siponimod 55%
  • ofatumumab 47%

• Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts

  Sharmin, S., Lefort, M., Andersen, J. B., Leray, E., Horakova, D., Havrdova, E. K., Alroughani, R., Izquierdo, G., Ozakbas, S., Patti, F., Onofrj, M., Lugaresi, A., Terzi, M., Grammond, P., Grand'Maison, F., Yamout, B., Prat, A., Girard, M., Duquette, P., Boz, C., & 31 flereTrojano, M., McCombe, P., Slee, M., Lechner-Scott, J., Turkoglu, R., Sola, P., Ferraro, D., Granella, F., Prevost, J., Maimone, D., Skibina, O., Buzzard, K., Van der Walt, A., Van Wijmeersch, B., Csepany, T., Spitaleri, D., Vucic, S., Casey, R., Debouverie, M., Edan, G., Ciron, J., Ruet, A., Sellebjerg, F. T., Soerensen, P. S., Jensen, M. B., Frederiksen, J. L., Bramow, S., Mathiesen, H. K., Schreiber, K. I., Magyari, M. & Danish Multiple Sclerosis Registry, OFSEP and the MSBase investigators, nov. 2021, I: CNS Drugs. 35, 11, s. 1217-1232 16 s.

  Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

  • Natalizumab 100%
  • Fingolimod Hydrochloride 96%
  • Relapsing-Remitting Multiple Sclerosis 86%
  • Recurrence 17%
  • Magnetic Resonance Imaging 15%
  4 Citationer (Scopus)

• Relapses add to permanent disability in relapsing multiple sclerosis patients

  Koch-Henriksen, N., Sørensen, P. S. & Magyari, M., aug. 2021, I: Multiple Sclerosis and Related Disorders. 53, s. 103029 103029.

  Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

  • Multiple Sclerosis 100%
  • Recurrence 64%
  • Denmark 10%
  • Secondary Prevention 10%
  • Therapeutics 8%

• Role of B Cells in Multiple Sclerosis and Related Disorders

  Sørensen, P. S. & Expert Panel of the 27th Annual Meeting of the European Charcot Foundation, jan. 2021, I: Annals of Neurology. 89, 1, s. 13-23 11 s.

  Publikation: Bidrag til tidsskrift › Review › peer review

  • Multiple Sclerosis 100%
  • B-Lymphocytes 87%
  • Chronic Progressive Multiple Sclerosis 31%
  • Neurodegenerative Diseases 19%
  • Direction compound 16%

• Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial

  Uccelli, A., Laroni, A., Ali, R., Battaglia, M. A., Blinkenberg, M., Brundin, L., Clanet, M., Fernandez, O., Marriot, J., Muraro, P., Nabavi, S. M., Oliveri, R. S., Radue, E., Ramo Tello, C., Schiavetti, I., Sellner, J., Sorensen, P. S., Sormani, M. P., Wuerfel, J. T., Freedman, M. S., & 1 flereMESEMS investigators, nov. 2021, I: The Lancet Neurology. 20, 11, s. 917-929 13 s.

  Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

  • Cross-Over Studies 100%
  • Mesenchymal Stem Cells 98%
  • Multiple Sclerosis 96%
  • Placebos 75%
  • Safety 64%

• The association of selected multiple sclerosis symptoms with disability and quality of life: a large Danish self-report survey

  Gustavsen, S., Olsson, A., Søndergaard, H. B., Andresen, S. R., Sørensen, P. S., Sellebjerg, F. & Oturai, A., 2021, I: BMC Neurology. 21, 1, 12 s., 317.

  Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

  • Self Report 100%
  • Multiple Sclerosis 99%
  • Quality of Life 72%
  • Fatigue 68%
  • Registries 63%

• The effectiveness of natalizumab vs fingolimod-A comparison of international registry studies

  Andersen, J. B., Sharmin, S., Lefort, M., Koch-Henriksen, N., Sellebjerg, F., Sørensen, P. S., Hilt Christensen, C. C., Rasmussen, P. V., Jensen, M. B., Frederiksen, J. L., Bramow, S., Mathiesen, H. K., Schreiber, K. I., Horakova, D., Havrdova, E. K., Alroughani, R., Izquierdo, G., Eichau, S., Ozakbas, S., Patti, F., & 66 flereOnofrj, M., Lugaresi, A., Terzi, M., Grammond, P., Grand Maison, F., Yamout, B., Prat, A., Girard, M., Duquette, P., Boz, C., Trojano, M., McCombe, P., Slee, M., Lechner-Scott, J., Turkoglu, R., Sola, P., Ferraro, D., Granella, F., Shaygannejad, V., Prevost, J., Skibina, O., Solaro, C., Karabudak, R., Wijmeersch, B. V., Csepany, T., Spitaleri, D., Vucic, S., Casey, R., Debouverie, M., Edan, G., Ciron, J., Ruet, A., Sèze, J. D., Maillart, E., Zephir, H., Labauge, P., Defer, G., Lebrun, C., Moreau, T., Berger, E., Clavelou, P., Pelletier, J., Stankoff, B., Gout, O., Thouvenot, E., Heinzlef, O., Al-Khedr, A., Bourre, B., Casez, O., Cabre, P., Montcuquet, A., Wahab, A., Camdessanché, J-P., Marousset, A., Patry, I., Hankiewicz, K., Pottier, C., Maubeuge, N., Labeyrie, C., Nifle, C., Leray, E., Laplaud, D. A., Butzkueven, H., Kalincik, T., Vukusic, S. & Magyari, M., aug. 2021, I: Multiple Sclerosis and Related Disorders. 53, s. 103012 103012.

  Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

  • Natalizumab 100%
  • Fingolimod Hydrochloride 96%
  • Registries 55%
  • Recurrence 17%
  • Epidemiologic Methods 13%

• The introduction of new medications in pediatric multiple sclerosis: Open issues and challenges

  Ghezzi, A., Amato, M. P., Edan, G., Hartung, H-P., Havrdová, E. K., Kappos, L., Montalban, X., Pozzilli, C., Trojano, M., Vermersch, P., Comi, G. & Sørensen, P. S., mar. 2021, I: Multiple Sclerosis Journal. 27, 3, s. 479-482 4 s.

  Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

  • Multiple Sclerosis 100%
  • Pediatrics 72%
  • Safety 49%
  • Fingolimod Hydrochloride 39%
  • Ethics 28%
  4 Citationer (Scopus)

• Transcriptome and Function of Novel Immunosuppressive Autoreactive Invariant Natural Killer T Cells That Are Absent in Progressive Multiple Sclerosis

  Carrión, B., Liu, Y., Hadi, M., Lundstrom, J., Christensen, J. R., Ammitzbøll, C., Dziegiel, M. H., Sørensen, P. S., Comabella, M., Montalban, X., Sellebjerg, F. & Issazadeh-Navikas, S., nov. 2021, I: Neurology: Neuroimmunology and NeuroInflammation. 8, 6

  Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

  • Natural Killer T-Cells 100%
  • Transcriptome 76%
  • Multiple Sclerosis 73%
  • Immunosuppressive Agents 69%
  • Tumor Necrosis Factor Receptors 19%

• Treatment Switching and Discontinuation Over 20 Years in the Big Multiple Sclerosis Data Network

  Hillert, J., Magyari, M., Soelberg Sørensen, P., Butzkueven, H., Van Der Welt, A., Vukusic, S., Trojano, M., Iaffaldano, P., Pellegrini, F., Hyde, R., Stawiarz, L., Manouchehrinia, A. & Spelman, T., 2021, I: Frontiers in Neurology. 12, s. 647811 647811.

  Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

  • Multiple Sclerosis 100%
  • Therapeutics 18%
  • N-acetyltalosaminuronic acid 10%
  • Observation 9%
  • Risk Management 7%
• 2020

  Aggressive multiple sclerosis (1): Towards a definition of the phenotype

  2018 ECTRIMS Focused Workshop Group, Frederiksen, J. L. B. & Sørensen, P. S., 2020, I: Multiple Sclerosis Journal. 26, 9, s. 1031-1044 14 s.

  Publikation: Bidrag til tidsskrift › Review › peer review

  • Multiple Sclerosis 100%
  • Phenotype 68%
  • Chronic Progressive Multiple Sclerosis 52%
  • Education 35%
  • Relapsing-Remitting Multiple Sclerosis 23%

• Aggressive multiple sclerosis (2): Treatment

  2018 ECTRIMS Focused Workshop Group, Frederiksen, J. L. B. & Sørensen, P. S., 12 jun. 2020, I: Multiple Sclerosis Journal. 26, 9, s. 1045-1063

  Publikation: Bidrag til tidsskrift › Review › peer review

  • Multiple Sclerosis 100%
  • Therapeutics 18%
  • Education 11%
  • Recurrence 10%

• Akut Medicin og Neurologi

  Feldt-Rasmussen, U. & Sørensen, P. S., 2020, Medicin. Lærebog i Medicin. Sømark, J. (red.). 3 udg. FADL's Forlag, Bind 1. s. 1101-1130 30 s.

  Publikation: Bidrag til bog/antologi/rapport › Bidrag til bog/antologi › Formidling

• Akut og intensiv neurologi

  Hansen, K. & Sørensen, P. S., 2020, Klinisk neurologi og neurokirurgi. 7 udg. FADL'S FORLAG, s. 236-267

  Publikation: Bidrag til bog/antologi/rapport › Bidrag til bog/antologi › Undervisning › peer review

• Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis

  Sellebjerg, F., Blinkenberg, M. & Sorensen, P. S., mar. 2020, I: CNS Drugs. 34, 3, s. 269-280 12 s.

  Publikation: Bidrag til tidsskrift › Review › peer review

  • Chronic Progressive Multiple Sclerosis 100%
  • Multiple Sclerosis 64%
  • Monoclonal Antibodies 53%
  • ocrelizumab 42%
  • B-Lymphocytes 37%

• Clinical characteristics and use of disease modifying therapy in the nationwide Danish cohort of paediatric onset multiple sclerosis

  Erdal, J. L., Kopp, T. I., Blinkenberg, M., Petersen, T., Sørensen, P. S. & Magyari, M., jan. 2020, I: Multiple Sclerosis and Related Disorders. 37, s. 101431

  Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

  • Multiple Sclerosis 100%
  • Pediatrics 72%
  • Child 24%
  • Therapeutics 18%
  • Natalizumab 16%

• Clinically stable disease is associated with a lower risk of both income loss and disability pension for patients with multiple sclerosis

  Chalmer, T. A., Buron, M., Illes, Z., Papp, V., Theodorsdottir, A., Schäfer, J., Hansen, V., Asgari, N., Skejø, P. B., Jensen, H. B., Sørensen, P. S. & Magyari, M., jan. 2020, I: Journal of neurology, neurosurgery, and psychiatry. 91, 1, s. 67-74 8 s.

  Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

  • Pensions 100%
  • Multiple Sclerosis 65%
  • Income 60%
  • Salaries and Fringe Benefits 44%
  • Proportional Hazards Models 11%

• Comorbidity in Multiple Sclerosis

  Magyari, M. & Sorensen, P. S., 21 aug. 2020, I: Frontiers in Neurology. 11, s. 851

  Publikation: Bidrag til tidsskrift › Review › peer review

  • Multiple Sclerosis 100%
  • Comorbidity 88%
  • Polypharmacy 15%
  • Patient Acceptance of Health Care 14%
  • Treatment Adherence and Compliance 14%

• Demyeliniserende sygdomme

  Sørensen, P. S. & Sellebjerg, F. T., 2020, Klinisk neurologi og neurokirurgi. 7 udg. København: FADL'S FORLAG, s. 620-646

  Publikation: Bidrag til bog/antologi/rapport › Bidrag til bog/antologi › Undervisning › peer review

• Det autonome nervesystem

  Sørensen, P. S. & Terkelsen, A. J., 2020, Klinisk neurologi og neurokirurgi, 7. udg.. 7 udg. FADL'S FORLAG, s. 110-131

  Publikation: Bidrag til bog/antologi/rapport › Bidrag til bog/antologi › Undervisning › peer review

• Det sensoriske system

  Sørensen, P. S. & Paulson, O. B., 2020, Klinisk neurologi og neurokirurgi. Paulson, O. B., Gjerris, F., Sørensen, P. S., Waldemar, G., Sørensen, J. C. H. & Sellebjerg, F. (red.). 7 udg. København: FADL'S FORLAG, s. 48-61 14 s.

  Publikation: Bidrag til bog/antologi/rapport › Bidrag til bog/antologi › Undervisning

• Effectiveness of glatiramer acetate in neutralizing antibody-positive patients previously treated with interferon-β

  Buron, M. D., Magyari, M., Chalmer, T. A., Sørensen, P. S. & Sellebjerg, F., apr. 2020, I: Multiple Sclerosis and Related Disorders. 39, s. 101894

  Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

  • Glatiramer Acetate 100%
  • Neutralizing Antibodies 68%
  • Interferons 63%
  • Confidence Intervals 8%
  • Multiple Sclerosis 8%

• Expert opinion on the use of cladribine tablets in clinical practice

  Sørensen, P. S., Centonze, D., Giovannoni, G., Montalban, X., Selchen, D., Vermersch, P., Wiendl, H., Yamout, B., Salloukh, H. & Rieckmann, P., jun. 2020, I: Therapeutic Advances in Neurological Disorders. 13, s. 1756286420935019

  Publikation: Bidrag til tidsskrift › Review › peer review

  • Cladribine 100%
  • Expert Testimony 71%
  • Tablets 62%
  • Multiple Sclerosis 40%
  • Guidelines 7%

• Initial high-efficacy disease-modifying therapy in multiple sclerosis: A nationwide cohort study

  Buron, M. D., Chalmer, T. A., Sellebjerg, F., Barzinji, I., Christensen, J. R., Christensen, M. K., Hansen, V., Illes, Z., Jensen, H. B., Kant, M., Papp, V., Petersen, T., Rasmussen, P. V., Schäfer, J., Theódórsdóttir, Á., Weglewski, A., Sorensen, P. S. & Magyari, M., 25 aug. 2020, I: Neurology. 95, 8, s. e1041-e1051 11 s., 32636328.

  Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

  • Multiple Sclerosis 100%
  • Cohort Studies 77%
  • Confidence Intervals 22%
  • Recurrence 21%
  • Therapeutics 18%